FDA Approves Fostamatinib for Chronic ITP

April 17, 2018 – The FDA has approved the SYK inhibitor fostamatinib as a second-line treatment for patients with chronic immune thrombocytopenia (ITP) following insufficient response to a previous therapy, based on findings from 2 randomized trials and 1 open-label extension study. In the first randomized study, known as FIT-1, 18% of patients treated with fostamatinib experienced a platelet response compared with none in the placebo arm. In the second study … (leggi tutto)